Biocon Biologics gets European marketing approval for Yesafili, biosimilar aflibercept

Biocon Biologics, a subsidiary of Biocon, has announced that the European Commission (EC) granted marketing authorization in the European Union (EU) for Yesafili, a biosimilar of aflibercept.
 
The EC decision follows the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) positive opinion recommending approval of Yesafili in July.
 
Yesafili, which is a registered trademark of Biocon Biologics is an ophthalmology product, is intended for the treatment of neovascular (wet AMD) age-related macular degeneration, visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DME) and visual impairment due to myopic choroidal neovascularisation (myopic CNV).  It is highly similar to the reference product Eylea (aflibercept). Data shows that Yesafili has comparable quality, safety, and efficacy to Eylea.
 
The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway.
 
Aflibercept had EU brand sales of approximately $1.8 billion for the 12 months ending December 31, 2022, according to IQVIA.
 
“We are very pleased to receive the European Commission’s approval of our Yesafili biosimilar as we continue to expand our biosimilar offerings across the globe, building on our oncology and diabetes product portfolio. We look forward to making a meaningful difference to patients in the EU impacted by macular degeneration and diabetic retinopathy, said the company spokesperson.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!